Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris
Main Article Content
Keywords
Acne Vulgaris, Acne, Tazarotene, retinoid
Abstract
References
2. Kircik LH Importance of vehicles in acne therapy J Drugs Dermatol 2011 Jun 10 6 s 17 23
3. Del Rosso JQ, Kircik LH, Zeichner J, Stein Gold L The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles Vehicle Characteristics Can Influence and Improve Patient Outcomes J Drugs Dermatol 2019 Feb 1 18 2 s) s 100 s 107
4. Eastman WJ, Malahias S, Delconte J, DiBenedetti D Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis Cutis 2014 Jul 94 1 46 53
5. Smith JA, Narahari S 2 Hill D, Feldman SR Tazarotene foam, 0 1 for the treatment of acne Expert Opin Drug Saf 2016 Jan 15 1 99 103
6. Feldman SR, Werner CP, Alió Saenz AB The efficacy and tolerability of tazarotene foam, 0 1 in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle controlled, double blind studies J Drugs Dermatol 2013 Apr 12 4 438 46
7. Epstein EL, Stein Gold L Safety and efficacy of tazarotene foam for the treatment of acne vulgaris Clin Cosmet Investig Dermatol 2013 May 14 6 123 5
8. Data on file, Mayne Pharma
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.